Analysts’ Recent Ratings Changes for Tenet Healthcare (THC)

Tenet Healthcare (NYSE: THC) has recently received a number of price target changes and ratings updates:

• 8/23/2026 – Tenet Healthcare was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 8/20/2026 – Tenet Healthcare was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
• 8/15/2026 – Tenet Healthcare was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 8/14/2026 – Tenet Healthcare had its “outperform” rating reaffirmed by Raymond James Financial, Inc.. They now have a $285.00 price target on the stock.
• 8/11/2026 – Tenet Healthcare was upgraded by Zacks Research from “hold” to “strong-buy”.
• 8/10/2026 – Tenet Healthcare was given a new $290.00 price target by Mizuho.
• 8/3/2026 – Tenet Healthcare had its price target raised by Wells Fargo & Company from $231.00 to $281.00. They now have an “overweight” rating on the stock.
• 8/3/2026 – Tenet Healthcare was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 7/28/2026 – Tenet Healthcare had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $305.00 price target on the stock.
• 7/28/2026 – Tenet Healthcare had its price target raised by Truist Financial Corporation from $270.00 to $290.00. They now have a “buy” rating on the stock.
• 7/28/2026 – Tenet Healthcare had its price target raised by Guggenheim from $242.00 to $283.00. They now have a “buy” rating on the stock.
• 7/28/2026 – Tenet Healthcare had its price target raised by Robert W. Baird from $210.00 to $280.00. They now have a “neutral” rating on the stock.
• 7/27/2026 – Tenet Healthcare had its “overweight” rating reaffirmed by Stephens. They now have a $285.00 price target on the stock.
• 7/27/2026 – Tenet Healthcare had its price target raised by UBS Group AG from $288.00 to $308.00. They now have a “buy” rating on the stock.
• 7/27/2026 – Tenet Healthcare was given a new $308.00 price target by Piper Sandler.
• 7/27/2026 – Tenet Healthcare had its price target raised by Morgan Stanley from $254.00 to $274.00. They now have an “overweight” rating on the stock.
• 7/27/2026 – Tenet Healthcare was given a new $270.00 price target by Raymond James Financial, Inc..
• 7/27/2026 – Tenet Healthcare had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 7/27/2026 – Tenet Healthcare had its price target raised by TD Cowen from $233.00 to $263.00. They now have a “buy” rating on the stock.
• 7/27/2026 – Tenet Healthcare had its price target raised by Royal Bank Of Canada from $236.00 to $283.00. They now have an “outperform” rating on the stock.
• 7/26/2026 – Tenet Healthcare was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/24/2026 – Tenet Healthcare had its price target raised by UBS Group AG from $288.00 to $308.00. They now have a “buy” rating on the stock.
• 7/24/2026 – Tenet Healthcare had its price target raised by Barclays PLC from $240.00 to $271.00. They now have an “overweight” rating on the stock.
• 7/20/2026 – Tenet Healthcare had its price target lowered by Guggenheim from $252.00 to $242.00. They now have a “buy” rating on the stock.
• 7/18/2026 – Tenet Healthcare was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/13/2026 – Tenet Healthcare had its price target raised by Wells Fargo & Company from $213.00 to $231.00. They now have an “overweight” rating on the stock.
• 7/8/2026 – Tenet Healthcare had its price target raised by Barclays PLC from $238.00 to $240.00. They now have an “overweight” rating on the stock.

Insider Activity

In other news, CEO Saumya Sutaria sold 50,000 shares of the stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $278.71, for a total transaction of $13,935,500.00. Following the completion of the transaction, the chief executive officer directly owned 483,564 shares in the company, valued at approximately $134,774,122.44. This represents a 9.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Tammy Romo sold 2,500 shares of the business’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $260.83, for a total transaction of $652,075.00. Following the completion of the sale, the director owned 28,284 shares in the company, valued at $7,377,315.72. This represents a 8.12% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 108,037 shares of company stock valued at $28,965,972 in the last three months. 0.97% of the stock is currently owned by insiders.

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.